Metformin Use and Severe Dengue in Diabetic Adults

Htet Lin Htun, Tsin Wen Yeo, Clarence C Tam, Junxiong Pang, Yee Sin Leo, David C Lye, Htet Lin Htun, Tsin Wen Yeo, Clarence C Tam, Junxiong Pang, Yee Sin Leo, David C Lye

Abstract

Diabetes mellitus is a risk factor for severe dengue in adults, but few studies have examined the association between metformin use and disease severity in dengue. In addition to its effect on glucose control, metformin has been associated with pleiotropic properties in preclinical studies. Using a cohort of laboratory-confirmed adult (≥21 years) dengue patients with diabetes mellitus admitted to Tan Tock Seng Hospital, we conducted a retrospective cohort study involving 131 (58.7%) metformin users and 92 (41.3%) non-users. Dengue severity was categorized as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) in World Health Organization (WHO) 1997 criteria and severe dengue (SD) in WHO 2009 criteria. Multivariable Poisson regression with robust error variance was used to estimate risk ratio (RR). Compared with non-use, metformin use was associated with a decreased risk of developing severe dengue (adjusted risk ratio [aRR] = 0.60, 95% confidence interval [CI]: 0.37-0.98, P = 0.04). Additionally, there was an inverse dose-response relationship (aRR = 0.69, 95% CI: 0.49-0.98, P = 0.04) with dengue severity as classified by WHO 2009 criteria. Use of metformin, however, was not associated with dengue severity based on WHO 1997 criteria; and no dose-response relationship was noted. Our results suggest metformin use could attenuate disease severity in dengue-infected diabetes mellitus individuals.

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flow diagram for selection of subjects.

References

    1. Murray NE, Quam MB, Wilder-Smith A. Epidemiology of dengue: past, present and future prospects. Clinical epidemiology. 2013;5:299–309.
    1. Simmons CP, Farrar JJ, van Vinh Chau N, Wills B. Dengue. New England Journal of Medicine. 2012;366:1423–1432. doi: 10.1056/NEJMra1110265.
    1. Bhatt S, et al. The global distribution and burden of dengue. Nature. 2013;496:504–507. doi: 10.1038/nature12060.
    1. Danaei G, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40. doi: 10.1016/S0140-6736(11)60679-X.
    1. Pernicova I, Korbonits M. Metformin–mode of action and clinical implications for diabetes and cancer. Nature reviews. Endocrinology. 2014;10:143–156. doi: 10.1038/nrendo.2013.256.
    1. McIntyre HD, et al. Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus. Australian and New Zealand journal of medicine. 1991;21:714–719. doi: 10.1111/j.1445-5994.1991.tb01375.x.
    1. Bailey CJ, Turner RC. Metformin. New England Journal of Medicine. 1996;334:574–579. doi: 10.1056/NEJM199602293340906.
    1. Isoda K, et al. Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells. Arteriosclerosis, thrombosis, and vascular biology. 2006;26:611–617. doi: 10.1161/01.ATV.0000201938.78044.75.
    1. Choi YK, Park KG. Metabolic roles of AMPK and metformin in cancer cells. Molecules and cells. 2013;36:279–287. doi: 10.1007/s10059-013-0169-8.
    1. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52:1766–1777. doi: 10.1007/s00125-009-1440-6.
    1. Forouzandeh F, et al. Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. Journal of the American Heart Association. 2014;3:e001202. doi: 10.1161/JAHA.114.001202.
    1. Singhal A, et al. Metformin as adjunct antituberculosis therapy. Science translational medicine. 2014;6:263ra159–263ra159. doi: 10.1126/scitranslmed.3009885.
    1. Shirazi F, et al. Diet modification and metformin have a beneficial effect in a fly model of obesity and mucormycosis. PloS one. 2014;9:e108635. doi: 10.1371/journal.pone.0108635.
    1. Xun YH, et al. Metformin inhibits hepatitis B virus protein production and replication in human hepatoma cells. Journal of viral hepatitis. 2014;21:597–603. doi: 10.1111/jvh.12187.
    1. Martina BE, Koraka P, Osterhaus AD. Dengue virus pathogenesis: an integrated view. Clinical microbiology reviews. 2009;22:564–581. doi: 10.1128/CMR.00035-09.
    1. Mahmood, S., Hafeez, S., Nabeel, H., Zahra, U. & Nazeer, H. Does comorbidity increase the risk of dengue hemorrhagic fever and dengue shock syndrome? ISRN Tropical Medicine2013 (2013).
    1. Figueiredo MAA, et al. Allergies and diabetes as risk factors for dengue hemorrhagic fever: results of a case control study. PLoS Negl Trop Dis. 2010;4:e699. doi: 10.1371/journal.pntd.0000699.
    1. Pang J, et al. Diabetes with hypertension as risk factors for adult dengue hemorrhagic fever in a predominantly dengue serotype 2 epidemic: a case control study. PLoS Negl Trop Dis. 2012;6:e1641. doi: 10.1371/journal.pntd.0001641.
    1. Pang, J., Hsu, J. P., Yeo, T. W., Leo, Y. S. & Lye, D. C. Diabetes, cardiac disorders and asthma as risk factors for severe organ involvement among adult dengue patients: A matched case-control study. Scientific reports7 (2017).
    1. Shih C-J, et al. Association between use of oral anti-diabetic drugs and the risk of sepsis: A nested case-control study. Scientific reports. 2015;5:15260. doi: 10.1038/srep15260.
    1. Ekstrom, N. et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ open2, 10.1136/bmjopen-2012-001076 (2012).
    1. Lee VJ, et al. Predictive value of simple clinical and laboratory variables for dengue hemorrhagic fever in adults. Journal of Clinical Virology. 2008;42:34–39. doi: 10.1016/j.jcv.2007.12.017.
    1. Lee TH, et al. Potential Harm of Prophylactic Platelet Transfusion in Adult Dengue Patients. PLoS Negl Trop Dis. 2016;10:e0004576. doi: 10.1371/journal.pntd.0004576.
    1. Barkham TM, Chung YK, Tang KF, Ooi EE. The performance of RT-PCR compared with a rapid serological assay for acute dengue fever in a diagnostic laboratory. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2006;100:142–148. doi: 10.1016/j.trstmh.2005.05.015.
    1. Gan VC, et al. Diagnosing dengue at the point-of-care: utility of a rapid combined diagnostic kit in Singapore. PLoS One. 2014;9:e90037. doi: 10.1371/journal.pone.0090037.
    1. Blacksell SD, et al. The comparative accuracy of 8 commercial rapid immunochromatographic assays for the diagnosis of acute dengue virus infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2006;42:1127–1134. doi: 10.1086/501358.
    1. World Health Organization. Dengue hemorrhagic fever: diagnosis, treatment, prevention and control. Geneva: World Health Organization (1997).
    1. World Health Organization et al. Dengue: guidelines for diagnosis, treatment, prevention and control. (World Health Organization, 2009).
    1. Wichmann O, et al. Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand. Tropical medicine & international health: TM & IH. 2004;9:1022–1029. doi: 10.1111/j.1365-3156.2004.01295.x.
    1. Hanafusa S, et al. Clinical features and differences between child and adult dengue infections in Rayong Province, southeast Thailand. Southeast Asian Journal of Tropical Medicine and Public Health. 2008;39:252.
    1. Sierra BdlC, Kouri G, Guzmán M. Race: a risk factor for dengue hemorrhagic fever. Archives of virology. 2007;152:533–542. doi: 10.1007/s00705-006-0869-x.
    1. Levri KM, et al. Metformin as treatment for overweight and obese adults: a systematic review. The Annals of Family Medicine. 2005;3:457–461. doi: 10.1370/afm.343.
    1. Pichainarong N, Mongkalangoon N, Kalayanarooj S, Chaveepojnkamjorn W. Relationship between body size and severity of dengue hemorrhagic fever among children aged 0-14 years. Southeast Asian journal of tropical medicine and public health. 2006;37:283.
    1. Sehdev A, et al. Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer. 2015;121:1071–1078. doi: 10.1002/cncr.29165.
    1. Yung CF, et al. Dengue serotype-specific differences in clinical manifestation, laboratory parameters and risk of severe disease in adults, singapore. The American journal of tropical medicine and hygiene. 2015;92:999–1005. doi: 10.4269/ajtmh.14-0628.
    1. Ministry of Health, S. Communicable Diseases Surveillance in Singapore 2013, (2013).
    1. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases. 1987;40:373–383. doi: 10.1016/0021-9681(87)90171-8.
    1. Toledo J, et al. Relevance of non-communicable comorbidities for the development of the severe forms of dengue: a systematic literature review. PLoS neglected tropical diseases. 2016;10:e0004284. doi: 10.1371/journal.pntd.0004284.
    1. Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321:405–412. doi: 10.1136/bmj.321.7258.405.
    1. Young BA, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. The American journal of managed care. 2008;14:15–23.
    1. Zou G. A modified poisson regression approach to prospective studies with binary data. American journal of epidemiology. 2004;159:702–706. doi: 10.1093/aje/kwh090.
    1. Zhang QS, et al. Metformin improves defective hematopoiesis and delays tumor formation in Fanconi anemia mice. Blood. 2016;128:2774–2784. doi: 10.1182/blood-2015-11-683490.
    1. Matsumoto T, et al. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. American journal of physiology. Heart and circulatory physiology. 2008;295:H1165–H1176. doi: 10.1152/ajpheart.00486.2008.
    1. Cheang WS, et al. Metformin protects endothelial function in diet-induced obese mice by inhibition of endoplasmic reticulum stress through 5′ adenosine monophosphate-activated protein kinase-peroxisome proliferator-activated receptor delta pathway. Arteriosclerosis, thrombosis, and vascular biology. 2014;34:830–836. doi: 10.1161/ATVBAHA.113.301938.
    1. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. Journal of the American College of Cardiology. 2001;37:1344–1350. doi: 10.1016/S0735-1097(01)01129-9.
    1. De Jager J, et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. Journal of internal medicine. 2005;257:100–109. doi: 10.1111/j.1365-2796.2004.01420.x.
    1. Gargiulo P, et al. Metformin decreases platelet superoxide anion production in diabetic patients. Diabetes/metabolism research and reviews. 2002;18:156–159. doi: 10.1002/dmrr.282.
    1. Gregorio F, et al. Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. Diabetic medicine: a journal of the British Diabetic Association. 1999;16:1016–1024. doi: 10.1046/j.1464-5491.1999.00201.x.
    1. Swaen G, van Amelsvoort L. A weight of evidence approach to causal inference. Journal of clinical epidemiology. 2009;62:270–277. doi: 10.1016/j.jclinepi.2008.06.013.
    1. Lye DC, Lee VJ, Sun Y, Leo YS. Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009;48:1262–1265. doi: 10.1086/597773.
    1. Khan Assir MZ, et al. Effectiveness of platelet transfusion in dengue Fever: a randomized controlled trial. Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie. 2013;40:362–368.
    1. Lye, D. C. et al. Prophylactic platelet transfusion plus supportive care versus supportive care alone in adults with dengue and thrombocytopenia: a multicentre, open-label, randomised, superiority trial. Lancet, 10.1016/S0140-6736(17)30269-6 (2017).

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner